Litigation Details for Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)
✉ Email this page to a colleague
Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)
| Docket | ⤷ Subscribe | Date Filed | 2016-09-22 |
| Court | District Court, D. Delaware | Date Terminated | 2020-09-08 |
| Cause | 35:271 Patent Infringement | Assigned To | |
| Jury Demand | None | Referred To | |
| Patents | 6,011,068; 6,211,244; 6,316,460; 9,375,405 | ||
| Firms | Phillips, McLaughlin & Hall, P.A. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Amgen Inc. v. Amneal Pharmaceuticals
The small molecule drugs covered by the patents cited in this case are ⤷ Subscribe and ⤷ Subscribe .
Biologic Drugs cited in Amgen Inc. v. Amneal Pharmaceuticals
The biologic drug covered by the patents cited in this case is ⤷ Subscribe .
Details for Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2016-12-14 | 14 | Status Report | and/or (c). Amgen also owns U.S. Patent No. 6,011,068, which is listed in the Orange Book listing…undergo parathyroidectomy. U.S. Patent No. 9,375,405 (the “’405 patent”) is listed in Approved Drug Products…‘405 patent invalid. 2. A judgment that no asserted claim of the ‘405 patent is infringed…Substance of the Actions These are Hatch-Waxman patent infringement actions relating to cinacalcet hydrochloride…United States prior to the expiration of the ’405 patent. By letter dated August 5, 2016, Aurobindo notified | External link to document |
| 2018-03-23 | 348 | Consent Judgment | admitted that Amgen’s United States Patent Number 9,375,405 (the “Amgen Patent”) is enforceable and valid. … Settlement Agreement, would infringe the Amgen Patent. 5. Defendants, including any of its successors…successors and assigns, are enjoined under the ’405 patent, and under any extensions and/or additional periods… or becomes entitled, from infringing the Amgen Patent, on its own part or through any Afflliate, by making…22 September 2016 1:16-cv-00853 830 Patent None District Court, D. Delaware | External link to document |
| 2018-04-19 | 357 | Memorandum Opinion | Defendants infringed United States Patent No. 9,375,405 (“the ’405 patent”) titled “Rapid Dissolution Formulation… 1. The ’405 Patent The ’405 patent issued from U.S. Patent Application No. 12/942,…OPINION This is a consolidated case for patent infringement brought by Plaintiff Amgen Inc. (…construed the meaning of the Markush groups in the ’405 patent; and (ii) Zydus’ Motion in Limine to preclude …case will be decided based on claim 1 of the ’405 patent, which states: (1) A pharmaceutical | External link to document |
| 2018-07-27 | 375 | Opinion | 2 through 24 as obvious “over Van Wagenen (US 6,211,244 B1) as evidenced by Kajiyama et al. (US 6,656,492…consolidated patent infringement action arising under the Drug Price Competition and Patent Term Restoration…Hatch-Waxman Act. United States Patent No. 9,375,405 (the “’405 patent”) is assigned to Plaintiff Amgen…BACKGROUND A. The ’405 Patent The ’405 patent, entitled “Rapid Dissolution Formulation… was issued by the United States Patent and Trademark Office (“Patent Office”) on June 28, 2016. (D.I | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
